quality control raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-18. Anything still debated is marked as such rather than presented as settled.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Alternatively, HBr and strong Lewis acids have been used, provided that a trap is provided for the released benzyl carbocation. When the protected amine is treated by either of the above methods (i.e. by catalytic hydrogenation or acidic workup), it yields a terminal carbamic acid which then readily decarboxylates to give the free amine. 2-Mercaptoethanol can also be used, in the presence of potassium phosphate in dimethylacetamide.
Glycine (symbol Gly or G; ) is an organic compound with the formula C2H5NO2, and is the simplest stable amino acid, distinguished by having a single hydrogen atom as its side chain. As one of the 20 proteinogenic amino acids, glycine is a fundamental building block of proteins in all life and is encoded by all codons starting with GG (GGU, GGC, GGA, and GGG). Because of its minimal side chain, it is the only common amino acid that is not chiral, meaning it is superimposable on its mirror image. In the body, glycine plays several crucial roles. Its small and flexible structure is vital for the formation of certain protein structures, most notably in collagen, where glycine makes up about 35% of the amino acid content and enables the tight coiling of the collagen triple helix. Glycine disrupts the formation of alpha-helices in secondary protein structure, in favor instead of random coils. Beyond its structural role, glycine functions as an inhibitory neurotransmitter in the central nervous system, particularly in the spinal cord and brainstem, where it helps regulate motor and sensory signals. Disruption of glycine signaling can lead to severe neurological disorders and motor dysfunction; for example, the tetanus toxin causes spastic paralysis by blocking glycine release. It also serves as a key precursor for the synthesis of other important biomolecules, including the porphyrins that form heme in blood and the purines used to build DNA and RNA. Glycine is a white, sweet-tasting crystalline solid, leading to its name from Greek word glykys (Greek: γλυκύς) or "sweet".
The Israelites, also known as the Children of Israel, were an ancient Semitic-speaking people who lived in Canaan during the Iron Age. They are associated with Hebrews and spoke Biblical Hebrew, an archaic Hebrew language. In the biblical myth, the Israelites were divided into the Twelve Tribes of Israel and later formed the Iron Age kingdoms of Israel and Judah. Modern scholarship describes the Israelites as emerging from indigenous Canaanite populations and other peoples of the ancient Near East. The Israelite religion revolved around Yahweh, who was an ancient Semitic god with less significance in the broader Canaanite religion. Around 720 BCE, the Kingdom of Israel was conquered by the Neo-Assyrian Empire, triggering the Assyrian captivity; and around 586 BCE, the Kingdom of Judah was conquered by the Neo-Babylonian Empire, triggering the Babylonian captivity. While most of Israel's population was irreversibly dispossessed as a result of Assyrian resettlement policy, the exiled Judahites were allowed to return and rehabilitate their country by the Achaemenid king Cyrus the Great following the fall of Babylon in 539 BCE. In the narrative of the Hebrew Bible, the Israelites were the descendants of Jacob (later known as Israel), who was a son of Isaac and thereby a grandson of Abraham. Due to a severe drought in Canaan, Jacob and his twelve sons migrated to Egypt, where each son became the eponymous progenitor of an Israelite tribe.
==== Swan Shiratori ==== Cignian Swan Shiratori (チーニョ星人 白鳥 スワン, Chīnyo Seijin Shiratori Suwan) is Kruger's intellectually and technologically gifted assistant from Planet Cigno who provides the Dekarangers with their arsenal. While she possesses a variant of the SP License called the Swan License (スワンライセンス, Suwan Raisensu), which grants her the ability to transform into the orange-colored Deka Swan (デカスワン, Deka Suwan), she has a personal policy to only do so once every four years, except for emergencies. As Deka Swan, she can perform either the Swan Illusion (スワンイリュージョン, Suwan Iryūjon) attack or the Swan Rainbow (スワンレインボー, Suwan Reinbō) finisher. Swan Shiratori is portrayed by Mako Ishino (石野 真子, Ishino Mako).
Sources: en.wikipedia.org
=== As a host for intracellular pathogens === In their role as a phagocytic immune cell macrophages are responsible for engulfing pathogens to destroy them. Some pathogens subvert this process and instead live inside the macrophage. This provides an environment in which the pathogen is hidden from the immune system and allows it to replicate. Diseases with this type of behaviour include tuberculosis (caused by Mycobacterium tuberculosis) and leishmaniasis (caused by Leishmania species). In order to minimize the possibility of becoming the host of an intracellular bacteria, macrophages have evolved defense mechanisms such as induction of nitric oxide and reactive oxygen intermediates, which are toxic to microbes. Macrophages have also evolved the ability to restrict the microbe's nutrient supply and induce autophagy.
=== Ruminants === Cattle that consume bracken ferns develop acute bracken poisoning and chronic bovine enzootic haematuria (BEH). The main feature of acute bracken poisoning in cattle is the depression of bone marrow activity, which gives rise to severe leucopenia (particularly of the granulocytes), thrombocytopenia, and acute haemorrhagic crisis. However, most of the researchers believe ptaquiloside is not the direct causing agent of the acute bracken fern poisoning. The main feature of haematuria is urinary bladder tumors and haematuria in cattle after prolonged exposure to bracken. Based on the extensive studies, a positive correlation is shown between the ptquiloside concentration and the incidence of BEH.
=== Emulsification === Sorbitan monooleate is used to stabilize emulsions by facilitating the mixture of non-miscible components like oil and water. It is particularly effective in forming stable W/O emulsions. It reduces the interfacial tension between oil and water phases in an emulsion. This lowered tension helps prevent the separation of the two phases, promoting a more stable emulsion.
=== Antiglobulin testing === The main method of antibody and antigen detection used in a clinical laboratory is red blood cell agglutination. Most IgM antibodies are easier to detect because they are larger and react at room temperature (20°C). This concept is what makes ABO/Rh testing so quick and easy to perform. However, most clinically significant non-ABO antibodies react at body temperature (37°C) and will not result in agglutination without the addition of multiple steps: incubation, washing, and the addition of anti-human globulin (AHG) reagent. Anti-human globulin is an antibody directed against human IgG antibodies. When the smaller IgG antibody is attached to red blood cells, the larger AHG antibodies create a cross-link between IgG sensitized RBC forming visual agglutination. When this agglutination is observed, the antiglobulin test is considered positive for the detection of the antibody and/or antigen(s) present. There are two main types of antiglobulin testing: indirect and direct. Indirect antiglobulin testing is used to detect antibodies in plasma/serum, whereas direct antiglobulin testing is used to detect antibody bound to red blood cells. When the direct antiglobulin test is positive, we must perform an antibody elution to remove the antibody for identification and to determine the antibody's clinical significance.
=== Nausea and vomiting === Tolerance to nausea occurs within 7–10 days, during which antiemetics (e.g. low dose haloperidol once at night) are very effective. Due to severe side effects such as tardive dyskinesia, haloperidol is now rarely used. A related drug, prochlorperazine is more often used, although it has similar risks. Stronger antiemetics such as ondansetron or tropisetron are sometimes used when nausea is severe or continuous and disturbing, despite their greater cost. A less expensive alternative is dopamine antagonists such as domperidone and metoclopramide. Domperidone does not cross the blood–brain barrier and produce adverse central antidopaminergic effects, but blocks opioid emetic action in the chemoreceptor trigger zone. This drug is not available in the U.S. Some antihistamines with anticholinergic properties (e.g. orphenadrine, diphenhydramine) may also be effective. The first-generation antihistamine hydroxyzine is commonly used, with the added advantages of not causing movement disorders, and also possessing analgesic-sparing properties. THC relieves nausea and vomiting; it also produces analgesia that may allow lower doses of opioids with reduced nausea and vomiting.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.